Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions

Epidiolex Phase III Ongoing

Executive Summary

After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.

You may also be interested in...



Japan Review/Outlook: Pricing Tweaks Considered After Year Of Change

After a year of revising and opening up its regulations for new drugs in 2023, Japan is aiming to add more reimbursement pricing premiums for innovative medicines in 2024, while cautiously discussing other detailed revisions to regulations and the pricing system.

Japan Moves To Lift Long-Standing Medical Cannabis Ban

Finally responding to pressure from domestic physicians, Japan has started discussions on the possible revision of long-standing regulations to allow the medical use of cannabis products, while putting in place strict measures to prevent illegal use or distribution.

Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck

Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel